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The potent inhibitors of protein kinase C (PKC), H7, staurosporine, and staurosporine derivatives, were examined for their inhibitory effects on 
novel PKC (nPKC) isozymes S and e. H7 and staurosporine, usually used as selective inhibitors of PKC, showed similar inhibitory effects on cPKC 
(a mixture of cPKCU, B, and y) and nPKCG and E. The inhibitory effects of K252a, a non-selective protein kinase inhibitor, on cPKC was 3.2- 
and 22-fold higher than those on nPKC.s and S, respectively. The staurosporine derivatives UCN-01 and UCN-Ol-Me also showed selective 
inhibition of cPKC. 
Protein kinase C; Novel PKC; PKC inhibitor 
1. INTRODUCTION 
Molecular cloning and biochemical studies on pro- 
tein kinase C (PKC) have revealed that purified brain 
PKC is a mixture of four isozymes (conventional PKC, 
cPKCCX, /II/II, and y) and have also demonstrated the 
presence of PKC-related proteins (novel PKC, nPKC& 
E, 9, 8, atypical PKCC, A) [1,2]. Since the latter group 
lack the putative Ca”-binding domain, they are consid- 
ered to be Ca2+-independent kinases. Analyses of the 
enzymological properties of nPKC& and 6 show that 
these nPKCs can also act as cellular targets for PKC 
activators such as diacylglycerol and phorbol esters as 
shown for conventional PKCs [3-6]. Expression of these 
nPKC members in a variety of cells and tissues [1,2] 
suggests the involvement of nPKC members in a com- 
plex cellular signaling system mediated by diacylglyc- 
erol and phorbol esters. Thus, discrimination of the role 
of each PKC member is essential to clarify the role of 
‘PKC’ in a variety of cellular signaling pathways. One 
promising way to this end is the molecular genetic ap- 
proach using type-specific DNAs, and another is the 
use of type-specific inhibitors. Although there are many 
reports in which PKC inhibitors such as H7 and stauro- 
sporine [7,8] are used that suggest he involvement of 
‘PKC’ in certain cellular functions, so far there is little 
information about the specificity of these PKC inhib- 
itors against nPKC members. 
In the present study, we examined the specificity of 
several widely used PKC inhibitors against nPKCS and 
E, and found that H7 and staurosporine are effective 
inhibitors against both conventional PKCs and nPKCG 
and E. Further, K252a and UCN-01 [8] are more selec- 
tive against conventional PKCs than against nPKCG 
and E. These results raise a possibility to identify PKC 
inhibitors which discriminate the involvement of these 
nPKC members in a variety of cell functions. 
2. MATERIALS AND METHODS 
2.1. Materials 
Bovine brain phosphatidylserine (PS) was purchased from Avanti 
Polar Lipid Inc.; 12-O-tetradecanoylphorbol-13-acetate (TPA) was 
from Sigma; [Y-‘~P]ATP was from DuPont-New England Nuclear. H7 
was obtained from Seikagaku Kogyo Co. Staurosporine, UCN-01, 
and K252a were isolated as previously described [9] and UCN-Ol-Me 
was synthesized according to a previous method [lo]. 
2.2. PKC assay 
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A PKC assay was performed as previously described using synthetic 
oligopeptide MBP,,, as a phosphate acceptor [4]. Each PKC isozyme 
in a 50 ml assay mixture (20 mM Tris-HCl, pH 7.5, 5 mM Mg(OAc),, 
0.5 mM CaCI,, 25 mg/ml of PS, 10 r&ml of TPA, 20 mM ATP, 0.5 
,&i [r-r*P]ATP, 50 mg/ml of MBP,,,, and 0.01% leupeptin) was 
incubated for 20 min at 3O’C in the presence or absence of various 
protein kinase inhibitors. 
3. RESULTS 
Abbreviations: PKC, protein kinase C; nPKC, novel PKC; cPKC, 
conventional PKC; PS, phosphatidylserine; TPA, 12-O-tetrade- 
canoylphorbol-13-acetate. 
To obtain sufficient amounts of PKC isozymes, 
cPKC (a mixture of cPKCa, PI/II, and y) and nPKC.s 
were purified from rabbit brain as previously described 
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Fig. 1. Western blot analyses of PKC isozymes preparations with 
antisera specific to PKC& (80 kDa), S (79 kDa), and E (90 kDa). 
Anti-PKCa does not cross-react with nPKCG or E. The 76-kDa band 
in lane 2 is an unknown protein in COS cells. Anti-nPKCGcross-reacts 
slightly with cPKC (lane 4). 
[5]. Since nPKCS is expressed in low amounts in rabbit 
brain, it was prepared from COS cells transfected with 
nPKCG cDNA plasmid [4]. These preparations were 
adjusted to contain 0.01% leupeptin, 0.01% bovine 
serum albumin, and 20% glycerol and stored at -80°C 
until use. Fig. 1 shows Western blot analyses of these 
PKC isozyme preparations with antisera specific to 
PKCcr and nPKCG and E [3,4]. 
First, we tried to examine the effects of H7 and stau- 
rosporine, which are widely used as PKC inhibitors. As 
shown in Table I, the IC,, values of both inhibitors for 
cPKC were consistent with those reported previously 
[8,11]. The K, values of staurosporine estimated by 
Dixon Plots for cPKCa and nPKCG and E were 0.77, 
3.5, and 0.86 nM, respectively. Although the effects of 
these inhibitors on each PKC isozyme were almost the 
same, the specificity of H7 was 6 > E > cPKC while that 
of staurosporine was E > cPKC > 6. On the other hand, 
UCN-01 and UCN-01-Me, which are the 7-hydroxy 
and 7-methoxy derivatives of staurosporine, respec- 
tively [lo], and are inhibitors more selective against 
PKC than staurosporine, had 2- to 7-fold weaker inhib- 
itory effects on nPKCG and nPKC& than on cPKC 
Table I 
Inhibitory effects of H7 and staurosporine related compounds on 
cPKC and nPKCG and E 
Inhibitors 1% (nM) SlcPKC &PKC 
cPKC nPKCS nPKC& 
H7 14,000 4,400 7,600 0.31 0.54 
Staurosporine 0.78 2.0 0.61 2.6 0.78 
UCN-01 1.1 8.0 5.5 7.3 5.0 
UCN-01-Me 1.0 1.9 4.6 1.9 4.6 
K252a 34 740 110 22 3.2 
ICsO values are the means of two or three experiments. 
(Table I). Since the optimal conditions to activate 
nPKCG and E are different from those of cPKC [3,4], we 
examined the effects of all of the inhibitors on PKC 
isozymes under various conditions, for example, in the 
absence of Ca*+ or in the presence of phosphatidylinos- 
itol or cardiolipin instead of PS. However, the inhib- 
itory effects on the PKC isozymes did not differ signifi- 
cantly under the various conditions tested (data not 
shown). 
The effects of K252a, a potent inhibitor of PKC and 
cyclic nucleotide-dependent kinases [ 121, on PKC 
isozymes were determined. As shown in Table I and Fig. 
2, the inhibitory activity of K252a on cPKC was 3.2- 
and 22-fold higher than on nPKC& and S, respectively. 
These effects did not change even when the assays were 
performed in the presence of phosphatidylinositol, a 
potent activator for nPKCG [4], instead of PS or in the 
absence of Ca2+ (data not shown). 
4. DISCUSSION 
nPKC differs from cPKC more clearly in terms of 
structural features of its regulatory domain than its ki- 
nase domain [1,2]. Especially, nPKC isozymes lack the 
putative Ca*+-binding domain and are fully activated 
even in the absence of Ca’+. Furthermore, the prefer- 
ences of the PKC isozymes for phospholipids, activa- 
tors of PKC, differ from each other [3,4]. On the other 
hand, the structures of catalytic domains of these 
isozymes are closely related, and the sequence of the 
ATP-binding site is conserved among them. Moreover, 
the kinase domain of PKC also shows sequence homol- 
ogy to other protein kinases, such as cyclic nucleotide- 
dependent kinases and calmodulin-dependent kinases. 
Therefore, PKC inhibitors targeted toward the catalytic 
domain show lower selectivity for PKC than those inter- 
acting with the regulatory domain [8]. Since all inhib- 
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Fig. 2. Inhibitory effects of K252a on cPKC (o), nPKCG (A), and 
nPKC& (m). Data are means of two or three experiments. 
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itors examined in this study are known to interact with 
the catalytic domain of PKC, one can speculate that 
they would fail to show high selectivity for the PKC 
isozymes. Indeed, H7 and staurosporine, one of the 
most widely used PKC inhibitors, show equipotent ef- 
fects on cPKC and nPKCG and E, consistent with the 
results reported previously [6,13]. Interestingly, the 
staurosporine-related compounds, UCN-01 and K252a, 
apparently distinguish nPKCS and E from cPKC (Table 
I). The effects of these inhibitors are independent of 
Ca2+ and phospholipids, PKC activators, suggesting 
that rather than recognizing the subtle conformational 
changes induced in the kinase domain upon activator 
binding, these inhibitors recognize structural differences 
in the kinase domains of PKC isozymes. 
K252a apparently exhibits its inhibitory activity 
against kinases in competition with ATP [12], but the 
exact mechanism of its action remains unclear. Al- 
though the ATP-binding site is conserved in cPKC and 
nPKCG and E, the I& values of K252a for cPKC and 
nPKCG differ by 22-fold. Tamaoki et al. [14] reported 
that the inhibitory effect of staurosporine, an analog of 
K252a, is not influenced by the presence of excess ATP 
These results suggest that K252a probably interacts 
with a site near, but clearly distinct from, the ATP- 
binding site. 
A potent and selective PKC inhibitor, UCN-01, is 
structurally different from staurosporine only in that 
the C-7 carbon bears a hydroxyl group; however, the 
stereoisomer of UCN-01 does not differ remarkably in 
its selectivity from staurosporine, implying that the se- 
lectivity of UCN-01 is due to the stereostructure at C-7 
[9]. Furthermore, 7-methoxy staurosporine, UCN-Ol- 
Me, shows a 3-fold greater potency and a 17-fold 
greater selective activity against PKC than UCN-01 
[lo]. When we compare the effects on PKC isozymes, 
however, UCN-01 showed the highest selectivity among 
the three inhibitors (Table I). Examining the effects of 
other staurosporine derivatives will reveal structural 
differences in the kinase domain not only between PKC 
and other protein kinases but also among closely related 
PKC isozymes. 
Recently, Marks and his colleagues purified a Ca2’- 
unresponsive, phorbol ester/phospholipid-activated 
protein kinase from porcine spleen that had a molecular 
weight of 76 kDa (p76-kinase) and was recognized by 
anti-nPKCG antibody [15,16]. The sensitivity of this 
partially purified p76-kinase towards K252a was two 
orders of magnitude lower than that of rat brain PKC 
[15], consistent with our results for nPKCG (Fig. 2). 
However, we could not observe the activation of 
nPKCG and E by K252a at low concentrations as was 
found for p76-kinase [141. Whether or not p76-kinase is 
a porcine nPKCG, it seems to be a member of the nPKC 
family and K252a can apparently distinguish nPKC 
isozymes from cPKC. 
K252a and UCN-01 can be useful in investigating the 
cellular functions of PKC isozymes. Ohmi et al. re- 
ported that H7 and staurosporine inhibited DNA syn- 
thesis of quiescent smooth muscle cells induced by 
serum and TPA equally, while K252a inhibited DNA 
synthesis induced by TPA more effectively than that 
induced by serum [17]. It is possible that in vascular 
smooth muscle cells, nPKC isozymes as well as cPKC 
isozymes are activated by TPA, but only PKC isozymes 
such as nPKCG and E, which have low sensitivity to 
K252a, are activated by serum. 
In order to clarify the cellular function of each of the 
PKC isozymes and to reveal structural differences 
among them, the staurosporine-related compounds 
K252a and UCN-01 will play an important role. 
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